Current Report Filing (8-k)
July 24 2020 - 9:38AM
Edgar (US Regulatory)
0001104506
false
0001104506
2020-07-24
2020-07-24
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or
15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event
reported): July 24, 2020
INSMED INCORPORATED
(Exact Name of Registrant as Specified
in Charter)
Virginia
|
|
000-30739
|
|
54-1972729
|
(State
or Other Jurisdiction
of
Incorporation)
|
|
(Commission
File
Number)
|
|
(I.R.S.
Employer
Identification
No.)
|
700 US Highway 202/206
Bridgewater, New Jersey 08807
(Address of Principal Executive Offices,and
Zip Code)
(908) 977-9900
Registrant’s Telephone Number, Including
Area Code
Not Applicable
(Former Name or Former Address, if Changed
Since Last Report)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see
General Instruction A.2. below):
¨
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement
communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement
communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of
the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common Stock, par value $0.01 per share
|
|
INSM
|
|
Nasdaq Global Select Market
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities
Exchange Act of 1934 (17 CFR 240.12b-2).
Emerging
growth company ¨
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with
any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
ITEM 7.01 – Regulation FD Disclosure.
On July 24, 2020, Insmed Incorporated issued
a press release with respect to the announcement summarized in Item 8.01 below. The press release is attached hereto as Exhibit
99.1 and is incorporated herein by reference.
ITEM 8.01 – Other Events.
On July 24, 2020, Insmed Incorporated announced
that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending
ARIKAYCE Liposomal 590 mg Nebuliser Dispersion for the treatment of non-tuberculous mycobacterial lung infections caused by Mycobacterium
avium complex in adults with limited treatment options who do not have cystic fibrosis. Consideration should be given to official
guidance on the appropriate use of antibacterial agents.
ITEM 9.01 - Financial Statements and Exhibits.
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: July 24, 2020
|
INSMED INCORPORATED
|
|
|
|
|
By:
|
/s/ Christine Pellizzari
|
|
Name:
|
Christine Pellizzari
|
|
Title:
|
Chief Legal Officer
|
Insmed (NASDAQ:INSM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Insmed (NASDAQ:INSM)
Historical Stock Chart
From Apr 2023 to Apr 2024